RxDoctor Payments Data

Jasneet Bhullar, MD

Colon & Rectal Surgery · Rochester Hills, MINPI 1316177876

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $42,900 of the $58,345 with a category attached, or 73.5%. Medtronic accounts for 93.0% of it on its own, with 14 other manufacturers making up the rest. Among colon & rectal surgery clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$58,345in general payments, 2019–2025

Across 156 payments — averaging $374.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$54K
  • Intuitive Surgical$3K
  • Johnson & Johnson$379
  • Inari Medical, Inc.$215
  • AbbVie$100
  • Takeda Pharmaceuticals U.S.A., Inc.$75
  • plus $345 from 9 others

What the payments were for

  • Speaking & faculty fees$42,90074%
  • Travel & lodging$9,90917%
  • Food & beverage$4,0227%
  • Education$1,5003%
  • Gifts$140%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,345 in reported general payments places this provider in the 90th percentile of 72 colon & rectal surgery providers in Michigan.

See all colon & rectal surgery providers in Michigan

Medicare billing

Part B allowed, 2024
$78,165
Medicare patients
212
Services billed
543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide11$8,789
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates14$1,096
Pantoprazole Sodium27$307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$100$8,78911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 72 colon & rectal surgery providers in Michigan.

Other colon & rectal surgery in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →